×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FULC – fulcrum therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FULC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
12:37 pm
fulc
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago [Yahoo! Finance]
12/11
07:22 am
fulc
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition [Yahoo! Finance]
Medium
Report
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition [Yahoo! Finance]
11/26
04:05 pm
fulc
Fulcrum Therapeutics to Participate in Upcoming December Conferences
High
Report
Fulcrum Therapeutics to Participate in Upcoming December Conferences
11/15
07:41 am
fulc
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) [Yahoo! Finance]
11/14
12:07 pm
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Neutral
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
11/14
08:15 am
fulc
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Medium
Report
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/14
02:21 am
fulc
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... [Yahoo! Finance]
11/13
07:00 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
Low
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
07:00 am
fulc
fulcrum therapeutics, inc.
BEAT
Report
-11.0%
fulcrum therapeutics, inc.
7/31/2024
07:00 am
fulc
fulcrum therapeutics, inc.
BEAT
Report
4.6%
fulcrum therapeutics, inc.
5/13/2024
07:00 am
fulc
fulcrum therapeutics, inc.
BEAT
Report
-13.1%
fulcrum therapeutics, inc.
2/27/2024
07:00 am
fulc
fulcrum therapeutics, inc.
BEAT
Report
8.5%
fulcrum therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/23
04:31 pm
fulc
Form 8-K Fulcrum Therapeutics, For: Dec 18
Low
Report
Form 8-K Fulcrum Therapeutics, For: Dec 18
12/6
04:29 pm
fulc
Form SC 13G Fulcrum Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Fulcrum Therapeutics, Filed by: BlackRock, Inc.
11/14
04:55 pm
fulc
Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: Nantahala Capital Management, LLC
Medium
Report
Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: Nantahala Capital Management, LLC
11/14
04:26 pm
fulc
Form SC 13G/A Fulcrum Therapeutics, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Medium
Report
Form SC 13G/A Fulcrum Therapeutics, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
11/14
04:15 pm
fulc
Form 4 Fulcrum Therapeutics, For: Nov 12 Filed by: King Rachel K.
Medium
Report
Form 4 Fulcrum Therapeutics, For: Nov 12 Filed by: King Rachel K.
11/14
04:11 pm
fulc
Form 3 Fulcrum Therapeutics, For: Nov 12 Filed by: King Rachel K.
Medium
Report
Form 3 Fulcrum Therapeutics, For: Nov 12 Filed by: King Rachel K.
11/14
06:15 am
fulc
Form SC 13G/A Fulcrum Therapeutics, Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SC 13G/A Fulcrum Therapeutics, Filed by: RTW INVESTMENTS, LP
11/13
07:11 am
fulc
Form 10-Q Fulcrum Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Fulcrum Therapeutics, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
25.0%
2/14 Form SC 13G Fulcrum Therapeutics, Filed by: GLAXOSMITHKLINE PLC 21.7%
8/19 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD 21.2%
12/17 Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC) [Yahoo! Finance News] 15.4%
10/30 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.1%
2/26 Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) 13.2%
2/20 Fulcrum Therapeutics to Participate in Upcoming Investor Conferences 10.3%
8/26 Form 8-K Fulcrum Therapeutics, For: Aug 26 8.8%
4/29 Form DEF 14A Fulcrum Therapeutics, For: Jun 11 8.6%
4/16 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 6.6%
2/14 Form SC 13G Fulcrum Therapeutics, Filed by: GLAXOSMITHKLINE PLC 21.7%
8/19 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD 21.2%
12/17 Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC) [Yahoo! Finance News] 15.4%
10/30 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.1%
2/26 Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) 13.2%
2/20 Fulcrum Therapeutics to Participate in Upcoming Investor Conferences 10.3%
8/26 Form 8-K Fulcrum Therapeutics, For: Aug 26 8.8%
4/29 Form DEF 14A Fulcrum Therapeutics, For: Jun 11 8.6%
4/16 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 6.6%
TOP News Decliners
8/1
Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
-12.9%
8/14 Form SEC STAFF LETTER Fulcrum Therapeutics, -10.3%
3/10 Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript [The Motley Fool] -9.2%
8/15 Fulcrum Therapeutics (NASDAQ: FULC) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. -8.8%
1/21 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.6%
7/17 Form 3 Fulcrum Therapeutics, For: Jul 17 Filed by: Third Rock Ventures GP IV, L.P. -6.9%
4/13 Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease -6.3%
7/18 Form 4 Fulcrum Therapeutics, For: Jul 18 Filed by: Cadavid Diego -6.3%
4/17 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
3/5 Form 10-K Fulcrum Therapeutics, For: Dec 31 -4.9%
8/14 Form SEC STAFF LETTER Fulcrum Therapeutics, -10.3%
3/10 Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript [The Motley Fool] -9.2%
8/15 Fulcrum Therapeutics (NASDAQ: FULC) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. -8.8%
1/21 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.6%
7/17 Form 3 Fulcrum Therapeutics, For: Jul 17 Filed by: Third Rock Ventures GP IV, L.P. -6.9%
4/13 Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease -6.3%
7/18 Form 4 Fulcrum Therapeutics, For: Jul 18 Filed by: Cadavid Diego -6.3%
4/17 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
3/5 Form 10-K Fulcrum Therapeutics, For: Dec 31 -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: